UNSPSC 51384510: Indoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CPE46ZU14N, chemically known as 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-methylbenzeneacetic acid but generally known as indoprofen, which bears US NIH Compound Identifier 3718. European Medicines Agency schedules Indoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08183MIG.

UNSPSC 51384510 Indoprofen is a Commodity code that nominally names a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code shows no solicitations for indoprofen itself. Instead, the three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products through cooperative purchasing. The code shows a mismatch between its nominal pharmaceutical scope and the actual procurement activity recorded against it. State and local issuing bodies—including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances—are using pharmaceutical codes to solicit broader categories of medicines, medical supplies, and pharmacy benefit program services rather than individual active pharmaceutical ingredients.

The geographic spread of recent activity includes Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the due date predates the posting date in the source and appears inconsistent). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs serving self-insured health plans and state agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The code shows little relevant recent activity aligned with its stated scope; firms should verify the actual commodity needed before pursuing opportunities tagged to this code.